Klin Farmakol Farm. 2025;39(2):84-88 | DOI: 10.36290/far.2025.035

Adverse effects of systemic treatment for psoriasis

David Suchý1, Petra Cetkovská2
1 Oddělení klinické farmakologie FN v Plzni
2 Dermatovenerologická klinika LF UK a FN v Plzni

Psoriasis is a chronic genetically determined immunologically mediated inflammatory condition associated with systemic comorbidities. Local therapy and phototherapy is usually recommended for mild psoriasis. When this treatment is not effective, not tolerated or contraindicated, as well as in patients with severe disease or significantly decreased quality of life the systemic therapy is prescribed. It is clinically important to consider the potential adverse events risks associated with the long-term use of synthetic oral and biological systemic therapies. The aim of this paper is to summarize profil of adverse events reported in context of psoriasis treatment

Keywords: psoriasis, systemic therapy, biological treatment, adverse effects.

Accepted: July 3, 2025; Published: July 4, 2025  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Suchý D, Cetkovská P. Adverse effects of systemic treatment for psoriasis. Klin Farmakol Farm. 2025;39(2):84-88. doi: 10.36290/far.2025.035.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. . Cetkovská P, Kojanová M, Arenberger P, et al. Současný stav moderní léčby psoriázy-aktualizovaná doporučení ČDS JEP k cílené léčbě závažné chronické psoriázy. Čes‑slov Derm. 2019;94(4):135‑164.
    2. . Benáková N. Moderní farmakoterapie v dermatologii. Jessenius. Praha: Maxdorf; 2023. ISBN 978‑80‑7345‑766‑2.
    3. . Amatore F, Villani A, Tabuer M, et al. French guidelines on the use of systemic treatments for moderate‑to‑severe psoriasis in adults. J Eur Acad Dermatol Venereol. 2019;33(3):464-483 [epub ahead of print]. Go to original source... Go to PubMed...
    4. . Katz H, Waalen J, Leach E. Acitretin in psoriasis: an overview of adverse effects. J Am Acad Dermatol. 1999;41:7‑12. Go to original source... Go to PubMed...
    5. . Ormerod AD, Campalani E, Goodfield MJ. British Association of Dermatologists guidelines on the efficacy and use of acitretin in dermatology. Br J Dermatol. 2010;162:952‑963. Go to original source... Go to PubMed...
    6. . Ormerod AD, Campalani E, Goodfield MJ. British Association of Dermatologists guidelines on the efficacy and use of acitretin in dermatology. Br J Dermatol. 2010;162:952‑963. Go to original source... Go to PubMed...
    7. . SÚKL. Rozhodnutí EK/dohoda CMDh k výsledkům PSUSA‑2018 [Internet]. Státní ústav pro kontrolu léčiv; 2018 [cited 2025-4-28]. Available from: http://www.sukl.cz/leciva/rozhodnuti‑ek‑dohoda‑cmdh‑k‑vysledkum‑psusa‑2018?highlightwords=psusa+2018.
    8. . Salavec M, Krejsek J. Apremilastum nové terapeutikum v léčbě psoriázy. Psoriasis News. 2017;2:6‑13.
    9. . Crowley J, Diamant T, Joly P, et al. Long-Term safety and tolerability of apremilast in patients with psoriasis: pooled safety analysis for >156 weeks from 2 phase 3, randomized, controlled trials (ESTEEM 1 and 2). J Am Acad Dermatol. 2017;77(2):310‑317. Go to original source... Go to PubMed...
    10. . Reszke R, Szepietowski JC. A safety evaluation of dimethyl fumarate in moderate to severe psoriasis. Expert Opin Drug Saf. 2020;19:373-380. Go to original source... Go to PubMed...
    11. . Dickel H, Bruckner T, Höxtermann S, et al. Fumaric acid ester-induced t-cell lymphopenia in the real-life treatment of psoriasis. J Eur Acad Dermatol Venereol. 2019;33:893-905. Go to original source... Go to PubMed...
    12. . Reich K, Mrowietz U, Radtke MA, et al. Drug safety of systemic treatments for psoriasis: results from the german psoriasis registry psobest. Arch Dermatol Res 2015;307:875-883. Go to original source... Go to PubMed...
    13. . Menter A, Strober BE, Kaplan DH, et al. Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with biologics. J Am Acad Dermatol. 2019;80(4):1029-1072 [epub ahead of print]. Go to original source... Go to PubMed...
    14. . Abramson A, Menter A, Perrillo R. Psoriasis, hepatitis B, and the tumor necrosis factor-alpha inhibitory agents: a review and recommendations for management. J Am Acad Dermatol. 2012;67:1349-1361. Go to original source... Go to PubMed...
    15. . Weisenseel P, Reich K. Paradoxical skin reactions under therapy with TNF‑α antagonists. Z Rheumatol. 2013;72:423‑428. Go to original source... Go to PubMed...
    16. . Langley RG, Elewski BE, Lebwohl M. Secukinumab in plaque psoriasis-results of two phase 3 trials N Engl J Med. 2014;371:326-338. Go to original source... Go to PubMed...
    17. . Gordon KB, Leonardi CL, Lebwohl M, et al. A 52- week, open-label study of the efficacy and safety of ixekizumab, an anti-interleukin- 17a monoclonal antibody, in patients with chronic plaque psoriasis. J Am Acad Dermatol. 2014;71:176-1182. Go to original source... Go to PubMed...
    18. . Gordon KB, Langley RG, Warren RB, et al. Bimekizumab safety in patients with moderate to severe plaque psoriasis: pooled results from phase 2 and phase 3 randomized clinicaltrials. JAMA Dermatol. 2022;58:735-744. Go to original source... Go to PubMed...
    19. . Saunte DM, Mrowietz U, Puig L, Zachariae C. Candida infections in patients with psoriasis and psoriatic arthritis treated with interleukin - 17 inhibitors and their practical management. Br J Dermatol 2017; 177:47-62. Go to original source... Go to PubMed...
    20. . Conti HR, Gaffen EN, et al. IL‑17‑mediated immunity to the opportunistic fungal pathogen Candida albicans. J Immunol. 2015;195:780‑788. Go to original source... Go to PubMed...
    21. . Tato CM, Cua DJ. Reconciling id, ego, and superego within interleukin‑23. Immunol Rev. 2008;226:103‑111. Go to original source... Go to PubMed...
    22. . Nogueira M, Torres T. Guselkumab for the treatment of psoriasis - evidence to date. Drugs Context. 2019;8:212594. Go to original source... Go to PubMed...
    23. . Papp KA, Blauvelt A, Bukhalo M, et al. Risankizumab versus ustekinumab for moderate‑to‑severe plaque psoriasis. N Engl J Med. 2017;376:1551‑1560. Go to original source... Go to PubMed...
    24. . Reich K, Papp KA, Blauvelt A, et al. Tildrakizumab versus placebo or etanercept for chronic plaque psoriasis (reSURFACE 1 and 2): results from two randomized controlled, phase 3 trials. Lancet. 2017;390:276‑288. Go to original source... Go to PubMed...
    25. . Brown G, Wang E, Leon A, et al. Tumor necrosis factor‑α inhibitor‑induced psoriasis: systematic review of clinical features, histopathological findings, and management experience. J Am Acad Dermatol. 2017;76:334‑341. Go to original source... Go to PubMed...
    26. . Deucravacitinib for moderate to severe psoriasis: a systematic review and meta‑analysis of randomized controlled trials. J Drugs Dermatol. 2024;23(2):67‑73.
    27. . Bristol‑Myers Squibb Company. SOTYKTU [package insert]. Princeton, NJ: Bristol‑Myers Squibb Company; 2022.

    Return to the content


    Clinical Pharmacology and Pharmacy

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.